

## Novel, Effective, and Differentiated Solutions for Skin Allergy Sufferers

Kenvue, a world leader in consumer health, is seeking novel or improved **over-the-counter solutions for sufferers of atopic dermatitis, allergic/ contact dermatitis, and urticaria**. The team is interested in treatments that are **more efficacious, faster acting, or have increased ease of use** compared to existing products.



### Approaches of Interest:

- Novel methods to **relieve the symptoms, prevent, and treat** skin allergies, including:
  - New combinations or methods with known ingredients
  - Repurposing of existing treatments and Rx-to-OTC switch
  - Improvements to existing therapies for faster or better relief
- Mechanisms of action of interest include maintaining the skin barrier, promoting a healthy inflammatory response, microbiome modulation (both skin and gut), immune modulation, and novel mechanisms with strong clinical evidence
- **Topical, oral, and nasal** solutions as well as **self-administered devices** are all of interest
- Solutions should improve on existing treatments based on **established clinical end points** (e.g. TADSI, IGA/PGA) or improvements in **patient reported quality of life**

### Out of Scope:

- Treatments for non-allergic skin conditions, angioedema, and polymorphic light eruptions
- Treatments that would require a prescription, including antibiotics
- Diagnostic medical devices

### Developmental Stages of Interest:

- Opportunities from Phase 1 onwards will be considered with Phase 2 onwards being of highest interest
- Opportunities with a quicker route to market will be given priority







### Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should include information on the critical technical milestones, costs, and risks (including regulatory strategy, technical risks, and supply chain) where possible. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

## Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

## Submissions

Please submit relevant, non-confidential opportunities to **Roisin McNally** at [rmcnally@usf.edu](mailto:rmcnally@usf.edu)

Deadline: **22nd November 2024 - 4:59 pm GMT**

**Have any questions?**

Contact **Roisin McNally** at [rmcnally@usf.edu](mailto:rmcnally@usf.edu)

